These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synthetic cephalosporins. VIII. Synthesis and antibacterial activity of CP6232, a new anti-pseudomonal cephalosporin. Sakagami K; Iwamatsu K; Atsumi K; Hatanaka M J Antibiot (Tokyo); 1992 Apr; 45(4):595-8. PubMed ID: 1592693 [No Abstract] [Full Text] [Related]
5. [Review of oral cephalosporins. Basis for a rational choice]. Forti IN Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980 [TBL] [Abstract][Full Text] [Related]
6. [HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin]. Chantot JF; Bryskier A Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):482-6. PubMed ID: 3937124 [TBL] [Abstract][Full Text] [Related]
9. [Cefoperazone in infections caused by resistant agents, with special reference to Pseudomonas aeruginosa]. Torres A; Vega J; Aguirre M; Alés JM Rev Clin Esp; 1982 Feb; 164(4):229-32. PubMed ID: 6211752 [No Abstract] [Full Text] [Related]
10. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents. Bell JM; Turnidge JD; Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610 [TBL] [Abstract][Full Text] [Related]
11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antibacterial activity of the new semisynthetic cephalosporin cefpirome. Mitsukude M; Inoue M; Mitsuhashi S Arzneimittelforschung; 1989 Jan; 39(1):26-30. PubMed ID: 2785801 [TBL] [Abstract][Full Text] [Related]
14. Cephalosporin antibiotics. Thompson RL; Wright AJ Mayo Clin Proc; 1983 Feb; 58(2):79-87. PubMed ID: 6401833 [TBL] [Abstract][Full Text] [Related]
15. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Alyaseen SA; Piper KE; Rouse MS; Steckelberg JM; Patel R Antimicrob Agents Chemother; 2005 Jun; 49(6):2543-5. PubMed ID: 15917569 [TBL] [Abstract][Full Text] [Related]
16. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa. Giske CG; Ge J; Nordmann P J Antimicrob Chemother; 2009 Aug; 64(2):430-1. PubMed ID: 19474066 [No Abstract] [Full Text] [Related]
17. In vitro and in vivo studies of ME1228, a new parenteral cephalosporin with potent activity against Pseudomonas aeruginosa. Miyazaki S; Miyazaki Y; Tsuji A; Nishida M; Goto S Antimicrob Agents Chemother; 1991 Jun; 35(6):1245-6. PubMed ID: 1929274 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon. Kanj SS; Chedid M; Araj GF J Med Liban; 2001; 49(1):13-7. PubMed ID: 11910959 [TBL] [Abstract][Full Text] [Related]
19. Cefpirome: epidemiological survey in intensive care units and hematological units in The Netherlands. The Dutch Study Group. Hoogkamp-Korstanje JA; Verduyn Lunel F; Meis JF Diagn Microbiol Infect Dis; 1998 Jul; 31(3):489-91. PubMed ID: 9635243 [No Abstract] [Full Text] [Related]